ACT Brief: Lilly Seeks FDA Priority Review for Oral GLP-1
Eli Lilly's orforglipron may become the first oral GLP-1 therapy reviewed under FDA's new national priority program.
Bispecific antibody research in oncology is redefining ethical standards, with the global BsAb market projected to quadruple by 2030.
- Orforglipron: a once-daily oral GLP-1 therapy.
- Bispecific antibodies: driving immuno-oncology innovation.
The global BsAb market is projected to quadruple by 2030.
Author's summary: Lilly seeks FDA priority review for oral GLP-1 therapy.
More News
- Ørsted secures $6.5bn from Apollo to co-fund Hornsea 3 offshore wind farm
- John Lewis Christmas advert music Where Loves Lives to become charity single
- John Lewis unveils tear-jerking Christmas advert set to iconic 90s club classic
- Ørsted sells 50% stake in Hornsea 3 offshore wind farm for $6.5bn
- Ghana's economy stabilising under President Mahama – Professor Opoku-Agyemang
- John Lewis 2025 Christmas advert stars classic '90s house banger